Apotex Pharmachem Inc.

What Apotex Pharmachem Inc. does

Apotex Pharmachem Inc., operating as Apotex Inc. and publicly traded as Apotex Health Corp. (TSX: APTX), is a Canadian-based global pharmaceutical company founded in 1974 and headquartered in Toronto, Ontario. It is described as Canada's largest pharmaceutical company and manufactures a diversified portfolio across four pillars: Generics, Biosimilars, Innovative and Specialty Medicines, and Consumer Health products, with dose manufacturing capacity supporting pharmaceutical production. The company recently expanded into the U.S. hospital injectable segment via the July 2026 launch of generic equivalents of Infuvite Adult and Pediatric Injection, two configurations of which carry Competitive Generic Therapy (CGT) exclusivity.

The company distributes its pharmaceutical and consumer health products directly to healthcare providers, pharmacies, and institutional customers across four operating geographies: Canada, the United States, Saudi Arabia, and Mexico. Its revenue model is built on the manufacture and sale of generic, biosimilar, specialty, and consumer health pharmaceuticals, with pricing not publicly disclosed. Operating geographies are supported by regional sites and direct sales channels targeting enterprise and institutional buyers.

Capital structure signals indicate a maturing public-company profile: Apotex secured an investment grade issuer rating from Morningstar DBRS and completed an Amended and Restated Credit Agreement in July 2026, and reports quarterly results (e.g., Q1 fiscal 2027 released August 2026). The company employs 5,821+ team members worldwide and has been operating for over 50 years, but no revenue figure, customer logos, AI/ML capabilities, or active M&A activity are disclosed in the input data.

Name

Apotex Pharmachem Inc.

Legal name

Apotex Inc.

Website

https://apotexpharmachem.com

Company type

Public

Founded year

1974

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Apotex Pharmachem Inc. is Canada's largest pharmaceutical company (TSX: APTX), manufacturing and distributing generics, biosimilars, specialty medicines, and consumer health products to healthcare providers, pharmacies, and institutional customers across Canada, the U.S., Saudi Arabia, and Mexico.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Specialty pharmaceuticals
• Consumer health products
• Pharmaceutical manufacturing

Headquarters

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Apotex generates revenue through the manufacture and sale of generic pharmaceuticals, biosimilars, innovative and specialty medicines, and consumer health products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Apotex is a Canadian-based global pharmaceutical company that manufactures and sells generic pharmaceuticals, biosimilars, innovative and specialty medicines, and consumer health products. The company operates dose manufacturing facilities and distributes its products directly to healthcare providers, pharmacies, and institutional customers across Canada, the United States, Saudi Arabia, and Mexico. Its portfolio targets both everyday therapeutic needs and complex conditions, with recent expansion into hospital-based injectable products.

Product overview

Apotex is a Canadian-based global health company and Canada's largest pharmaceutical company offering a diversified portfolio of pharmaceutical products. The company operates as a single unified product portfolio comprising four main product categories: Generics (affordable alternatives to brand-name medications), Biosimilars (biologic medications similar to reference products), Innovative & Specialty Medicines (targeting complex conditions), and Consumer Health (over-the-counter products). Recently, the company has expanded into hospital-based injectable products such as the Generic Infuvite Adult and Pediatric Injection. With 5821+ team members worldwide, Apotex serves multiple countries and maintains dose manufacturing capacity across its pharmaceutical and consumer health product lines.

Differentiator

Problem solved

Functional benefit

Products and services

• Generics
• Biosimilars
• Innovative & Specialty Medicines
• Consumer Health
• Generic Infuvite Adult and Pediatric Injection

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Viatris: Global pharmaceutical company formed from the Mylan-Upjohn merger, with a substantial generics and biosimilar portfolio across developed and emerging markets, directly comparable to Apotex's product mix.
• Bausch Health: Canadian-headquartered pharmaceutical company with diversified branded generics, specialty, and consumer health products — directly comparable as a fellow Canadian pharma incumbent with overlapping portfolio categories.
• Aurobindo Pharma: Vertically integrated Indian generic pharmaceutical manufacturer with a global footprint across the U.S., Europe, and emerging markets, comparable to Apotex's generics manufacturing scale and product breadth.
• Endo International: Specialty and generics pharmaceutical company with meaningful U.S. hospital injectable franchise, directly comparable to Apotex's recent U.S. hospital push with generic Infuvite.
• Sun Pharmaceutical Industries: India-based global generic and specialty pharmaceutical manufacturer with significant U.S. and emerging market presence, comparable to Apotex's generics manufacturing model and geographic diversification goals.
• Dr. Reddy's Laboratories: Indian multinational pharmaceutical company with a generics, biosimilars, and specialty portfolio across the U.S. and other key markets, comparable in product mix to Apotex.
• Sandoz: Novartis's generic and biosimilar-focused spinoff with a global footprint across generics, biosimilars, and specialty, directly comparable to Apotex's portfolio breadth and manufacturing-driven business model.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with a diversified specialty and biosimilar portfolio, directly comparable to Apotex across generics, biosimilars, and specialty medicines with global manufacturing scale.
• Hikma Pharmaceuticals: Generics and specialty pharmaceutical manufacturer with strength in the U.S. hospital injectable channel and Middle East presence, directly comparable to Apotex's hospital expansion strategy and geographic mix.

Emerging players

• Lannett: U.S.-focused generic pharmaceutical manufacturer with emphasis on affordable generics, comparable as a North America-focused generics peer though smaller and less diversified than Apotex.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/apotex-pharmachem-inc.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apotex Pharmachem Inc.